Storia in 3 fonti

ResMed Analyst Backs Portfolio Reset - ResMed (NYSE:RMD)

ResMed is selling MatrixCare for $490 million to sharpen its sleep health focus as analysts weigh near-term EPS dilution against long-term growth.

Raccontata da

afr.com

thenextweb.com

benzinga.com

Confronto fonti

3 prospettive sulla stessa storia

AI · summaries

benzinga.comStai leggendo7 g fa

ResMed Analyst Backs Portfolio Reset - ResMed (NYSE:RMD)

ResMed is selling MatrixCare for $490 million to sharpen its sleep health focus as analysts weigh near-term EPS dilution against long-term growth.

originale

thenextweb.com9 g fa

ResMed sells its MatrixCare software business to Frazier for $490m

ResMed is selling its MatrixCare home-health software unit to Frazier Healthcare Partners for $490m in cash to focus on sleep and breathing care.

Leggi questa versione → originale

afr.com9 g fa

Resmed sells US software business on the cheap as AI threat looms

The medical device maker has sold the MatrixCare business for less than it bought it for eight years ago, with analysts pointing to potential AI disruption.

Leggi questa versione → originale

Timeline cronologica

mercoledì 8 luglio 2026·afr.com
Resmed sells US software business on the cheap as AI threat looms
The medical device maker has sold the MatrixCare business for less than it bought it for eight years ago, with analysts pointing to potential AI disruption.
mercoledì 8 luglio 2026·thenextweb.com
ResMed sells its MatrixCare software business to Frazier for $490m
ResMed is selling its MatrixCare home-health software unit to Frazier Healthcare Partners for $490m in cash to focus on sleep and breathing care.
giovedì 9 luglio 2026·benzinga.com
ResMed Analyst Backs Portfolio Reset - ResMed (NYSE:RMD)
ResMed is selling MatrixCare for $490 million to sharpen its sleep health focus as analysts weigh near-term EPS dilution against long-term growth.